Istradefylline reduces motor fluctuations in Parkinson's disease
This article has no abstract so we have provided the first paragraph of the full text.
The efficacy of levodopa therapy for Parkinson's disease (PD) declines with time, and some patients experience breakthrough motor symptoms as doses wear off. These motor fluctuations are caused by an overactive striatopallidal output pathway, so they could potentially be alleviated by blockade of A2A adenosine receptors on striatopallidal neurons. To test this theory, LeWitt and colleagues investigated the effects of istradefylline, a selective adenosine A2A receptor antagonist, in patients with PD who were receiving levodopa therapy.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.